Weekly GLP-1 receptor agonist. Brand: Trulicity. Established CV risk reduction in T2D from REWIND (2019). ~5-day half-life. Manufacturer: Eli Lilly.
Pharmacology
Weekly GLP-1 receptor agonist. Brand: Trulicity. Established CV risk reduction in T2D from REWIND (2019). ~5-day half-life. Manufacturer: Eli Lilly.
FDA-approved indications
- Type 2 diabetes — 2014
- CV risk reduction in T2D with established CVD or multiple CV risk factors — 2020; basis: REWIND
Standard dosing
- Starting: 0.75 mg weekly
- Titration: 1.5 → 3.0 → 4.5 mg weekly
Side effects
- Common class side effects (GI)
- Same MTC/MEN-2 boxed warning
Compounded availability
Compounded dulaglutide uncommon. Dulaglutide was not on FDA's shortage list during the recent shortage period.
See also
· Research bibliography · Drug interactions · Where to get it (compounded)